Basel, Switzerland (ots/PRNewswire) - - First Ever Economic Analysis Shows Tamiflu Use in a Pandemic Could Save Significant Costs to Society Treatment with the oral antiviral Tamiflu (oseltamivir) and prophylaxis for people exposed to infected patients could be one of the most cost-effective strategies for reducing illness and death during an influenza ...
Indianapolis and Brussels, Belgium (ots/PRNewswire) - - Global contest seeks expressions of the triumphs and challenges of living with diabetes through art, essay, poetry, photography and music Eli Lilly and Company and the International Diabetes Federation (IDF) today announced the global launch of the ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today that its proprietary Duocalin® technology has successfully demonstrated dual targeting potential. Commenting on this development, Dr ...
Alderley Park, England (ots/PRNewswire) - - FOR NON-US HEALTHCARE PROFESSIONAL PRESS ONLY - AstraZeneca Collaborates With Myriad Genetics on Phase 2 Trials AstraZeneca (NYSE: AZN) today announced the start of two Phase II trials for a new compound being tested to treat patients with BRCA 1 & 2 ...
pro adicta - escape Ambulatorium
Schoeftland (ots) - pro adicta facilitates the treatment of addiction to opioids such as heroin and methadone by means of escape, an innovative method of treatment using neuroelectric stimulation. Drug addiction can be overcome more easily using neuronal stimulation. On the basis of the latest knowledge in the ...
Oss, The Netherlands (ots/PRNewswire) - Organon announced today that NuvaRing(R) (etonogestrel/ethinyl estradiol vaginal ring), the company's once-a-month contraceptive, has successfully completed the European Mutual Recognition Procedure (MRP) in an additional 13 countries (1). NuvaRing is already approved in 14 European Union territories using the Mutual ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced that it is at the final stage of concluding the Exchange Offer it launched for all of the outstanding shares of ISOTIS SA on December 15, 2006. After this last step of the Exchange Offer, ISOTIS SA will no longer be listed on SWX Swiss Exchange, Euronext Amsterdam and the Toronto Stock Exchange. On ...
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was presented at the European Society of Hypertension, Milan. The results from ...
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media - Results From Two Large, Multinational, Practice-Based Observational Studies in Blood Pressure New data announced today at the Annual European Society of Hypertension (ESH) show that measuring blood pressure in a doctor's office alone does ...
Astellas Pharma Europe Limited
London (ots/PRNewswire) - Astellas today announced that Advagraf(R) (generic name: tacrolimus, prolonged release), a once-daily immunosuppressant for use in organ transplantation, is now available in Germany and the UK. The European Commission approved Advagraf(R) on April 23, 2007 for the prophylaxis of ...
Beerse, Belgium (ots/PRNewswire) - Janssen-Cilag International NV has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for ceftobiprole, an investigational antibiotic for the treatment of complicated skin and soft tissue infections (cSSTI) including diabetic foot ...
Malvern, Pennsylvania (ots/PRNewswire) - Solstice Neurosciences, Inc. today reported important results from a multicenter, forced dose escalation study of Botulinum Toxin Type B Injectable Solution (Myobloc(R)) recently presented at the 11th International Congress of The Movement Disorders Society in ...
London (ots/PRNewswire) - - First Treatment Licensed Specifically for LGS Offers New Hope for Patients With Epilepsy Eisai Europe Limited, (Headquarters: London, President Yutaka Tsuchiya) today announced the launch in Germany and Scandinavia of its new anti-epileptic agent Inovelon (rufinamide) indicated for adjunctive therapy in Lennox-Gastaut Syndrome ...
Basel, Switzerland (ots/PRNewswire) - - New Data Supports IL-6 Receptor Inhibition as a Key Component in Controlling Inflammation From RA Roche today announced significant results from 'OPTION'(1), the first rheumatoid arthritis multinational phase III study of Actemra (tocilizumab) outside of Japan. The ...
Basel, Switzerland (ots/PRNewswire) - Eight presentations regarding Roche's new anti-anaemia drug MIRCERA(R) currently awaiting approval worldwide, will feature strongly at the upcoming European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Barcelona Spain, June 21st to 24th 2007. Three MIRCERA abstracts have received the ...
Copenhagen, Denmark (ots/PRNewswire) - - Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Combination With CHOP as Front Line Treatment of Follicular NHL. Genmab A/S (CSE: GEN) announced today it has initiated a Phase II study of ofatumumab (HuMax-CD20(R)) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with previously untreated follicular ...
Global Lung Cancer Coalition (GLCC)
London (ots/PRNewswire) - The Lung Cancer Journalism Awards' mission: to raise global awareness of the leading cause of cancer-related deaths worldwide. Winners receive: - Global showcase recognising their prize-winning work - EUR7,000 research grant Enter to win 3 different ...
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim GmbH announced today that it has begun to enroll patients in the SPRING study. The SPRING study will be one of the largest racially and gender diverse international studies of highly treatment-experienced HIV-1 infected patients. The trial ...
Barcelona (ots) - New Results Represent Additional Data From a Study Showing Superior Efficacy of ORENCIA or Infliximab Compared to Placebo at Six Months Bristol-Myers Squibb Company (NYSE: BMY) today announced additional study results providing evidence of the efficacy and durability of response of ORENCIA(R) (abatacept) through 12 months in adults with ...
Anti-Tumor Necrosis Factor (TNF) Therapy in Inadequately Responding Rheumatoid Arthritis Patients Barcelona (ots) - According to a new study, it is possible to safely switch directly to ORENCIA® from anti-TNF therapy in rheumatoid arthritis patients who have had an inadequate response to anti-TNF therapy. The results were announced today by Bristol-Myers ...
Oss, The Netherlands (ots/PRNewswire) - Sugammadex - the novel selective relaxant binding agent (SRBA) being developed by Organon, the human healthcare business unit of Akzo Nobel - demonstrated in a Phase III pivotal trial a 9-12 times faster reversal of neuromuscular blockade as compared to neostigmine, without ...
Ingelheim Am Rhein, Germany (ots/PRNewswire) - - Studies Reinforce the Benefits of Pramipexole From Daytime Symptom Control, Including Afternoon and Early Evening Onset - For Healthcare Media Outside the U.S.A. New data demonstrate that pramipexole (Mirapexin(R)/Sifrol(R)) is also efficacious and ...
Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) - www.isotechnika.com Isotechnika today announced that the Company has received a No Objection Letter from Health Canada for the long term use of ISA247 in patients currently participating in the Canadian arm of the Company's Phase 2b kidney transplant trial. The No ...
Brussels (ots/PRNewswire) - Led by British MEP Liz Lynne, medical experts and representatives of relevant patient and professional associations today called on the European Commission and the Council to recognise asthma as a serious public health issue. The statement is part of the Brussels Declaration, a 10-point action plan for improving asthma management across ...
Basel, Switzerland (ots/PRNewswire) - - First Publication of Phase III Data in the Clinical Journal of the American Society of Nephrology Results from a multi-centre renal anaemia study show that switching patients directly from frequent doses of epoetin therapies (epoetin alfa or beta administered one to ...
Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) Isotechnika Inc. announced today that the Company received approval from the Polish Competent Authority for participation in the ongoing Phase 3 European/Canadian clinical trial. This trial investigates the use of ISA247 ...
Chicago (ots/PRNewswire) - - Oral Xeloda(R) Combination Effective and Time-Saving Data presented today at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago showed that not only is XELOX as effective as intravenous (i.v.) drug regimens, but that colorectal cancer patients who ...
Alderley Park, England (ots/PRNewswire) - - FOR NON-US/NON-UK MEDICAL MEDIA ONLY ALDERLEY PARK, England, June 4 /PRNewswire/ -- AstraZeneca (LSE: AZN; NYSE: AZN) today announced details of two new investigational cancer therapies at the American Society of Clinical Oncology (ASCO) meeting. AZD2281 (KU-0059436) is a small molecule inhibitor of ...
Chicago, Illinois (ots/PRNewswire) - - One Year Results From the ARIBON Study Presented at ASCO 2007 Bondronat(R) (ibandronic acid) has been shown to prevent bone loss caused by anastrozole in post-menopausal women given adjuvant therapy for early breast cancer according to results from the ARIBON ...
Chicago (ots/PRNewswire) - - Five Phase III Early-Stage Breast Cancer Studies Underway With GEMZAR GEMZAR(R) (gemcitabine HC1 for injection), approved in combination with paclitaxel (Taxol(R)) in the first-line, post-surgical treatment of metastatic breast cancer, was the subject of a study ...